We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifteenth stock that takes place on our list is 4D Molecular Therapeutics, Inc. TheFly reported on January 27 that Barclays initiated coverage of FDMT with an Overweight rating and a $33 price target. Positive considerations for FDMT and the group in 2026 included the biotech industry’s solid fundamentals, the undervaluation of several companies, anticipated tailwinds from mergers and acquisitions, and a decreased emphasis ...

Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Company Overview - 4D Molecular Therapeutics is focused on developing innovative solutions for retinal care, aiming to eliminate the need for lifelong injections [2][3] - The company is led by Dr. David Kirn, who serves as the Co-Founder and CEO [2] Product Pipeline - The lead product candidate of 4D Molecular Therapeutics is 4D-150, which targets neovascular diseases of the retina [3] - The presentation will outline the company's recent accomplishments and future potential, particularly regarding 4D-150 [2][3] Market Potential - The presentation will discuss the size and growth of the markets related to retinal care, highlighting significant unmet medical needs [3] - There is an emphasis on the importance of addressing these unmet needs to capture market opportunities [3] Development Strategy - The company will outline its strategy for Phase III trials and commercialization, focusing on derisking the approval process and enhancing commercial potential [3]

Summary of 4D Molecular Therapeutics FY Conference Call Company Overview - **Company**: 4D Molecular Therapeutics (NasdaqGS:FDMT) - **Industry**: Biotechnology, specifically focusing on genetic medicines for retinal diseases Core Points and Arguments Product Pipeline and Development - **Lead Product**: 4D-150, targeting neovascular diseases of the retina, specifically wet AMD and diabetic macular edema (DME) [2][3] - **Clinical Trials**: Two ongoing Phase 3 trials for wet AMD with excellent enrollment; a Phase 3 trial for DME expected to initiate in Q3 2026 [4][6] - **Safety and Efficacy**: Strong Phase 1 and 2 results reported, with no significant inflammation observed in over 80 patients [5][6][26] - **Durability**: Promises a significant reduction in treatment burden, with an 80-90% reduction in the need for injections compared to traditional therapies [24][30] Market Opportunity - **Market Size**: The retinal vascular disease market is approximately $17 billion annually, with $14 billion specifically for wet AMD and DME [12] - **Patient Population**: Approximately 9 million people in the U.S., Europe, and Japan suffer from these diseases, with 600,000 new diagnoses each year [12][13] - **Unmet Needs**: Current treatments require lifelong injections, leading to high discontinuation rates (40% within a year) due to the burden of therapy [17][18] Regulatory and Commercial Strategy - **Regulatory Designations**: Received RMAT designation for DME and wet AMD, indicating recognition of the unmet medical need [7][32] - **Partnerships**: Collaboration with Otsuka for Asia-Pacific rights, retaining U.S. and European rights; the deal includes $135 million in upfront and cost coverage [4][49] - **Financial Position**: Closed a $100 million raise in Q4 2025, providing a runway into the second half of 2028 [8][39] Team and Expertise - **Leadership Team**: Comprised of industry veterans with extensive experience in retina therapeutics, including prior roles at Novartis and Iveric [10][11] - **External Engagement**: Strong pre-commercial team engaging with physicians, indicating high interest in gene therapy solutions [44][46] Additional Important Content - **Patient Journey**: Emphasizes the emotional and psychological burden of current treatment regimens on patients, highlighting the need for a more manageable solution [13][14][15] - **Innovative Delivery**: Utilizes a proprietary capsid for safe, low-dose intravitreal injections, aiming for continuous expression of aflibercept [25][41] - **Market Differentiation**: Positioned as a unique offering in the gene therapy space, distinct from traditional TKIs, with a focus on long-term durability and reduced treatment burden [46][47] Future Catalysts - **Upcoming Milestones**: Expected completion of Phase 3 enrollment for wet AMD in Q1 2026 and DME in Q2 2026, with top-line data anticipated in the first half of 2027 [38][39] - **Financial Outlook**: Strong cash position expected to support ongoing clinical activities and potential commercialization efforts [39]

The New Backbone of Retina Care: Moving Beyond Lifelong Injections Corporate Overview J.P. Morgan Healthcare Conference | January 2026 This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities. © 2026 4D Molecular Therapeutics. All Rights Reserved. 2 Overview 1 4DMT Vision & Pipeline 2 4D-150 Overview & 2025 Accomplishments 3 Retinal Vascular Disease Market & Unmet Medical Needs 4 Derisking Phase 3 & Commercialization 5 2026-27 Catalysts 6 Summary © 2026 4D Mo ...

Core Insights - 4D Molecular Therapeutics (4DMT) is advancing its lead product candidate, 4D-150, aimed at treating retinal vascular diseases, with significant milestones expected in 2026 [1][14] Leadership Changes - Glenn P. Sblendorio has joined the Board of Directors, bringing extensive experience from IVERIC Bio and The Medicines Company, which will support the company's late-stage execution and commercial readiness [3][7] - Katy Barglow, Ph.D., has been promoted to Chief Technical Officer, overseeing the transition to commercial manufacturing [12] - Kim Maplestone has been promoted to Chief Clinical Operations Officer, responsible for global clinical operations [12] - Chris Simms' role has expanded to Chief Commercial & Business Officer, including business development oversight [12] - Fred Kamal, Ph.D., has transitioned to Chief Technical Advisor, supporting CMC and regulatory strategy for 4D-150 [12] Clinical Development Updates - Enrollment in the 4D-150 Phase 3 wet AMD clinical trials is exceeding expectations, with 381 patients randomized or approved to randomize as of January 6, 2026, and completion expected in Q1 2026 [4][5] - The target enrollment for the 4FRONT Global Phase 3 Program has increased from 400 to 480 patients per trial, providing approximately 90% power for regulatory success [5] - Topline data from the 4FRONT-1 trial is expected in H1 2027, while the 4FRONT-2 trial is on track for completion in H2 2026 [5] - 4D-150's Phase 2b data from the PRISM trial is expected to be presented in mid-2026 [4][5] Financial Position - As of December 31, 2025, the company reported $514 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2028 [9] Upcoming Events - The company will present its strategic outlook at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 7:30 a.m. PT [10]

Company Overview - 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) is a California-based late-stage biotechnology company specializing in adeno-associated virus vectors, founded in 2013. The company operates through a proprietary synthetic vector discovery platform known as Therapeutic Vector Evolution [5]. Investment Potential - 4D Molecular Therapeutics, Inc. is considered one of the best stocks for rapid wealth accumulation, with 82% of analysts covering the stock giving it a 'Buy' or equivalent rating. The price target ranges from $17 to $45, with a one-year median price target of $33, indicating an upside potential of over 300% [1]. Clinical Trial Results - On December 17, the company reported positive interim clinical data from its 4D-710 Phase 1 AEROW clinical trial targeting cystic fibrosis lung disease. The higher-dose cohorts showed no new pulmonary or safety events over up to 3.5 years of follow-up, and any unfavorable events related to 4D-710 were mild and resolvable within 2 months in lower-dose cohorts [3]. - Airway biopsy and brushing outcomes indicated stable and dose-dependent CFTR transgene RNA levels at or above physiologically relevant levels compared to non-CF control samples. In the 2.5E14 vg dose cohort, results aligned with the target expression profile, showing meaningful activity across all endpoints, particularly ppFEV1 and LCI2.5 [4]. Insider Activity - On December 19, Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics, sold 1,635 shares of the company's stock for approximately $17,821 [2].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - The newsletter is led by a biotech consultant with over 5 years of experience, who has compiled detailed reports on more than 1,000 companies [1] - The investing group, Haggerston BioHealth, caters to both novice and experienced investors, providing insights on product sales, forecasts for major pharmaceutical companies, and various financial analyses [1]

Group 1 - U.S. stock futures were mostly higher, with Nasdaq 100 futures gaining around 100 points [1] - BlackBerry reported third-quarter revenue of $141.8 million, exceeding analyst estimates of $137.4 million [2] - BlackBerry's adjusted earnings were 5 cents per share, beating estimates of 4 cents per share [2] Group 2 - BlackBerry's total revenue decreased approximately 1% year-over-year, while QNX revenue grew by 10% [2] - BlackBerry shares fell 4.6% to $4.13 in pre-market trading [2] - Aimei Health Technology Co Ltd shares dropped 15.8% to $44.00 after a significant increase the previous day [3] - Nike Inc shares decreased 9.9% to $59.11 despite better-than-expected earnings and sales, due to a decline in gross margins [3] - FedEx Corp shares fell 2.2% to $281.00, despite posting strong financial results and raising FY2026 guidance [3]

Core Viewpoint - The company is discussing interim Phase I data from the AEROW trial focused on cystic fibrosis, indicating progress in their research and development efforts [2]. Group 1: Company Overview - The call features key personnel including the Co-Founder and CEO, the Lead Principal Investigator from National Jewish Health, and a Co-Head from the Cystic Fibrosis Center at SickKids Research Institute [4]. - The company encourages stakeholders to visit their Investor Relations website for further details, including a press release and access to the webcast recording [2]. Group 2: Research and Development - The AEROW trial is a significant focus for the company, highlighting their commitment to advancing treatment options for cystic fibrosis [2]. - The involvement of leading experts in the field, such as Dr. Jennifer Taylor-Cousar and Dr. Felix Ratjen, underscores the trial's credibility and potential impact [4].